Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Section 6 of 6

References

196 sources

  1. Agrawal et al. (2023) (opens in a new tab)
  2. Agrawal et al. (2026) (opens in a new tab)
  3. Albert et al. (2023) (opens in a new tab)
  4. Aqneursa prescribing information (2026) (opens in a new tab)
  5. Aston et al. (2019) (opens in a new tab)
  6. Beren Therapeutics ACMG data press release (2026) (opens in a new tab)
  7. Beren Therapeutics Breakthrough Therapy designation press release (2025) (opens in a new tab)
  8. Beren Therapeutics CNS data press release (2026) (opens in a new tab)
  9. Beren Therapeutics financing press release (2026) (opens in a new tab)
  10. Beren Therapeutics LEMBAZ approval community update (2026) (opens in a new tab)
  11. Beren Therapeutics LEMBAZ approval press release (2026) (opens in a new tab)
  12. Beren Therapeutics NDA acceptance press release (2026) (opens in a new tab)
  13. Beren Therapeutics NDA submission community letter (2025) (opens in a new tab)
  14. Beren Therapeutics NDA submission press release (2025) (opens in a new tab)
  15. Beren Therapeutics October 2024 community update (2024) (opens in a new tab)
  16. Beren Therapeutics October 2025 community update (2025) (opens in a new tab)
  17. Beren Therapeutics patent estate press release (2026) (opens in a new tab)
  18. Beren Therapeutics review extension press release (2026) (opens in a new tab)
  19. Beren Therapeutics September 2024 community update (2024) (opens in a new tab)
  20. Beren Therapeutics test for NPC press release (2026) (opens in a new tab)
  21. Beren Therapeutics webinar community update (2026) (opens in a new tab)
  22. Berry-Kravis et al. (2018) (opens in a new tab)
  23. Berry-Kravis et al. (2025) (opens in a new tab)
  24. Berry-Kravis et al. (2026a) (opens in a new tab)
  25. Berry-Kravis et al. (2026b) (opens in a new tab)
  26. Berry-Kravis et al. (2026c) (opens in a new tab)
  27. Berry-Kravis et al. (2026d) (opens in a new tab)
  28. Berry-Kravis et al. (2026e) (opens in a new tab)
  29. Berry-Kravis et al. (2026f) (opens in a new tab)
  30. Berry-Kravis et al. (2026g) (opens in a new tab)
  31. Bianconi et al. (2019) (opens in a new tab)
  32. Bolton et al. (2022) (opens in a new tab)
  33. Bonney et al. (2010) (opens in a new tab)
  34. Bountouvi et al. (2021) (opens in a new tab)
  35. Breen et al. (2013) (opens in a new tab)
  36. Bremova-Ertl and Patterson (2025) (opens in a new tab)
  37. Bremova-Ertl et al. (2022) (opens in a new tab)
  38. Bremova-Ertl et al. (2024) (opens in a new tab)
  39. Burchard et al. (2026a) (opens in a new tab)
  40. Burchard et al. (2026b) (opens in a new tab)
  41. Burton et al. (2021) (opens in a new tab)
  42. California Department of Health Care Access and Information Prescription Drugs Introduced to Market (2026) (opens in a new tab)
  43. California Department of Health Care Access and Information Prescription Drugs Introduced to Market, MIPLYFFA (2026) (opens in a new tab)
  44. Cawley et al. (2025) (opens in a new tab)
  45. ClinicalTrials.gov NCT00344331 (opens in a new tab)
  46. ClinicalTrials.gov NCT01747135 (opens in a new tab)
  47. ClinicalTrials.gov NCT02534844 (opens in a new tab)
  48. ClinicalTrials.gov NCT02534844 API record (opens in a new tab)
  49. ClinicalTrials.gov NCT02534844 results (opens in a new tab)
  50. ClinicalTrials.gov NCT03643562 (opens in a new tab)
  51. ClinicalTrials.gov NCT03643562 API record (opens in a new tab)
  52. ClinicalTrials.gov NCT03643562 results (opens in a new tab)
  53. ClinicalTrials.gov NCT03879655 (opens in a new tab)
  54. ClinicalTrials.gov NCT03879655 results (opens in a new tab)
  55. ClinicalTrials.gov NCT04860960 (opens in a new tab)
  56. ClinicalTrials.gov NCT04958642 (opens in a new tab)
  57. ClinicalTrials.gov NCT04958642 results (opens in a new tab)
  58. ClinicalTrials.gov NCT05368038 (opens in a new tab)
  59. ClinicalTrials.gov NCT07054515 (opens in a new tab)
  60. CMS Clinical Laboratory Fee Schedule (2026) (opens in a new tab)
  61. Crumling et al. (2017) (opens in a new tab)
  62. Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026) (opens in a new tab)
  63. Diaz et al. (2022) (opens in a new tab)
  64. Drugs.com Lembaz FDA approval history (2026) (opens in a new tab)
  65. Drugs@FDA NDA 219132 (opens in a new tab)
  66. Drugs@FDA NDA 220996 (opens in a new tab)
  67. EMA orphan designation EU/3/13/1124 (2013) (opens in a new tab)
  68. Erickson and Fiorenza (2017) (opens in a new tab)
  69. European Medicines Agency Aqneursa EPAR (2026) (opens in a new tab)
  70. European Medicines Agency Meplyffa refusal (2026) (opens in a new tab)
  71. European Medicines Agency Meplyffa refusal questions and answers (2026) (opens in a new tab)
  72. European Medicines Agency Zavesca product information (2026) (opens in a new tab)
  73. Evans et al. (2021) (opens in a new tab)
  74. Farhat et al. (2022) (opens in a new tab)
  75. Farmer et al. (2019) (opens in a new tab)
  76. Farmer et al. (2026) (opens in a new tab)
  77. FDA (2024) (opens in a new tab)
  78. FDA Lembaz approval press announcement (2026) (opens in a new tab)
  79. FDA Miplyffa approval announcement (2024) (opens in a new tab)
  80. FDA NDA 220996 approval letter (2026) (opens in a new tab)
  81. FDA NDA approval letter (2024) (opens in a new tab)
  82. FDA Orphan Drug Designations and Approvals (2013) (opens in a new tab)
  83. Fierce Pharma LEMBAZ approval report (2026) (opens in a new tab)
  84. Fierce Pharma phase 3 results report (2026) (opens in a new tab)
  85. Freihuber et al. (2023) (opens in a new tab)
  86. Garver et al. (2007) (opens in a new tab)
  87. Gascón-Bayarri et al. (2022) (opens in a new tab)
  88. GeneDx Zevra NPC sponsored genetic testing program press release (2026) (opens in a new tab)
  89. Golden et al. (2023) (opens in a new tab)
  90. Gutić et al. (2022) (opens in a new tab)
  91. Hastings et al. (2019) (opens in a new tab)
  92. Héron et al. (2012) (opens in a new tab)
  93. Hiwot et al. (2026) (opens in a new tab)
  94. ICER Launch Price and Access Report (2026) (opens in a new tab)
  95. Imrie et al. (2009) (opens in a new tab)
  96. Jiang et al. (2014) (opens in a new tab)
  97. Jiang et al. (2016) (opens in a new tab)
  98. Jiang et al. (2019) (opens in a new tab)
  99. Jiao et al. (2026) (opens in a new tab)
  100. Julich et al. (2026) (opens in a new tab)
  101. Kao et al. (2020) (opens in a new tab)
  102. King et al. (2014) (opens in a new tab)
  103. Koens et al. (2016) (opens in a new tab)
  104. Labrecque et al. (2021) (opens in a new tab)
  105. LEMBAZ billing and coding guide (2026) (opens in a new tab)
  106. LEMBAZ caregiver website (2026) (opens in a new tab)
  107. LEMBAZ dosing and administration guide (2026) (opens in a new tab)
  108. LEMBAZ Family Support terms and conditions (2026) (opens in a new tab)
  109. LEMBAZ letter of medical necessity template (2026) (opens in a new tab)
  110. LEMBAZ patient enrollment form (2026) (opens in a new tab)
  111. Lembaz prescribing information (2026) (opens in a new tab)
  112. LEMBAZ prior authorization checklist (2026) (opens in a new tab)
  113. Maarup et al. (2015) (opens in a new tab)
  114. Mallinckrodt Form 10-K (2019) (opens in a new tab)
  115. Mallinckrodt Form 10-K (2020) (opens in a new tab)
  116. Mallinckrodt plan of reorganization exhibit (2021) (opens in a new tab)
  117. Mallinckrodt VTS-270-001 protocol (2021) (opens in a new tab)
  118. Mandos December 2021 community update (2021) (opens in a new tab)
  119. Mandos expanded access program continuation letter (2021) (opens in a new tab)
  120. Mandos Health survival and biomarker analyses press release (2025) (opens in a new tab)
  121. Mandos May 2022 community update (2022) (opens in a new tab)
  122. Mandos November 2022 community update (2022) (opens in a new tab)
  123. Matsuo et al. (2014) (opens in a new tab)
  124. Matsuo et al. (2024) (opens in a new tab)
  125. Medicaid.gov State Drug Utilization Data 2025 (2026) (opens in a new tab)
  126. Medicaid.gov State Drug Utilization Data 2025 for MIPLYFFA (2026) (opens in a new tab)
  127. Medicaid.gov State Drug Utilization Data 2026 (2026) (opens in a new tab)
  128. Medicaid.gov State Drug Utilization Data 2026 for MIPLYFFA (2026) (opens in a new tab)
  129. Medscape adrabetadex drug monograph (2026) (opens in a new tab)
  130. Mengel et al. (2020) (opens in a new tab)
  131. Mengel et al. (2021a) (opens in a new tab)
  132. Mengel et al. (2021b) (opens in a new tab)
  133. Mengel et al. (2025a) (opens in a new tab)
  134. Mengel et al. (2025b) (opens in a new tab)
  135. Mengel et al. (2026) (opens in a new tab)
  136. Miplyffa prescribing information (2024) (opens in a new tab)
  137. Modin et al. (2021) (opens in a new tab)
  138. Nafees et al. (2026) (opens in a new tab)
  139. New York State Medicaid eMedNY (opens in a new tab)
  140. New York State Medicaid list of reimbursable drugs (2026) (opens in a new tab)
  141. NHS England Specialised Services Quality Dashboard lysosomal storage disorders metric definitions (2022) (opens in a new tab)
  142. NICE arimoclomol appraisal (2022) (opens in a new tab)
  143. NICE VTS-270 appraisal (2026) (opens in a new tab)
  144. NICHD phase 1-2a trial news release (2017) (opens in a new tab)
  145. Oklahoma Health Care Authority Drug Utilization Review Board packet (2025) (opens in a new tab)
  146. Ontario Exceptional Access Program Zavesca reimbursement guidelines (2011) (opens in a new tab)
  147. Oregon State University Drug Use Research and Management Program (2025) (opens in a new tab)
  148. Orphazyme complete response letter announcement (2021) (opens in a new tab)
  149. Ory et al. (2017) (opens in a new tab)
  150. Ottinger et al. (2014) (opens in a new tab)
  151. Padilla et al. (2025) (opens in a new tab)
  152. Patterson et al. (2007) (opens in a new tab)
  153. Patterson et al. (2010) (opens in a new tab)
  154. Patterson et al. (2015) (opens in a new tab)
  155. Patterson et al. (2020a) (opens in a new tab)
  156. Patterson et al. (2020b) (opens in a new tab)
  157. Patterson et al. (2021) (opens in a new tab)
  158. Patterson et al. (2025) (opens in a new tab)
  159. Pharmaphorum LEMBAZ approval report (2026) (opens in a new tab)
  160. Pineda et al. (2016) (opens in a new tab)
  161. Porter et al. (2025) (opens in a new tab)
  162. Porter et al. (2026) (opens in a new tab)
  163. Rafael Holdings Form 10-K (2026) (opens in a new tab)
  164. Rafael Holdings investor presentation (2026) (opens in a new tab)
  165. Rafael Holdings TransportNPC topline results release (2026) (opens in a new tab)
  166. Roch Santed et al. (2017) (opens in a new tab)
  167. Rodriguez-Gil et al. (2025) (opens in a new tab)
  168. Scottish Medicines Consortium (2010) (opens in a new tab)
  169. Sharma et al. (2023) (opens in a new tab)
  170. Sharma et al. (2026) (opens in a new tab)
  171. Sidhu et al. (2020) (opens in a new tab)
  172. Solomon et al. (2020) (opens in a new tab)
  173. Solomon et al. (2026) (opens in a new tab)
  174. Sucampo Vtesse acquisition press release (2017) (opens in a new tab)
  175. Tchan et al. (2026) (opens in a new tab)
  176. Texas Department of State Health Services 2025 Annual WAC Report (2026) (opens in a new tab)
  177. Texas Department of State Health Services 2026 Annual WAC Report (2026) (opens in a new tab)
  178. Texas Department of State Health Services Prescription Drug Price Disclosure Program data overview (opens in a new tab)
  179. van Karnebeek et al. (2015) (opens in a new tab)
  180. Vanier (2010) (opens in a new tab)
  181. Vite et al. (2015) (opens in a new tab)
  182. Vtesse Breakthrough Therapy designation press release (2016) (opens in a new tab)
  183. Vtesse VTS-270-302 protocol (2021) (opens in a new tab)
  184. Vtesse VTS301 protocol amendment 15 (2021) (opens in a new tab)
  185. Vtesse VTS301 protocol synopsis (2019) (opens in a new tab)
  186. Vtesse VTS301 statistical analysis plan (2018) (opens in a new tab)
  187. Walterfang et al. (2012) (opens in a new tab)
  188. Wassif et al. (2016) (opens in a new tab)
  189. Wraith et al. (2010) (opens in a new tab)
  190. Yanjanin et al. (2010) (opens in a new tab)
  191. Yergey et al. (2017) (opens in a new tab)
  192. YODA Project data request 2021-4741 (opens in a new tab)
  193. ZAVESCA prescribing information (2020) (opens in a new tab)
  194. Zevra Therapeutics advisory committee release (2024) (opens in a new tab)
  195. Zevra Therapeutics Form 10-K (2026) (opens in a new tab)
  196. Zevra Therapeutics third quarter 2026 results release (2026) (opens in a new tab)